BioResearchAgent

20 gold tasks

Task explorer

Every task is grounded in a specific sentence of a specific frozen abstract — see each task's construction note for exactly which one, and whether it's a real question or a deliberate hallucination trap.
IDTypeDomainDifficultyStatusQuestion
A1Direct factual retrievalprotein biologyeasyAnswerableAccording to the corpus, what kind of protein does the TP53 gene encode and what is its canonical function?
A2Direct factual retrievalprotein biologyeasyAnswerableAccording to the corpus, what is BRCA1 and what cellular processes does it participate in?
B1Evidence aggregationdisease mechanismsmediumAnswerableWhat experimental evidence in the corpus supports a mechanistic link between mutant p53 and immune suppression?
C1ComparisongeneticsmediumAnswerableCompare BRCA1 and PALB2 as characterized in the corpus: what do they have in common and how do they differ?
E1Multi-hop synthesisprotein biologyhardAnswerableVia what intermediate binding partner does BRCA1 reach downstream DNA-repair effector proteins, according to the corpus, and which effectors are named?
F1Contradiction handlingdisease mechanismshardAnswerable, with caveatIs the finding that breast-cancer risk after ovarian cancer in germline BRCA1/2 carriers is lower than expected a settled consensus in the corpus, or is it contested/being re-evaluated?
G1Insufficient evidence (trap)protein biologymediumTrap — no answer existsDoes the corpus provide evidence that DDIAS directly binds or interacts with BRCA1?
G2Insufficient evidence (trap)geneticsmediumTrap — no answer existsDoes the corpus provide evidence that EGFR regulates TP53-mutation-driven immune suppression?
D1Relation extractionprotein biologymediumAnswerableExtract the gene/protein relationship(s) describing how BARD1 relates to BRCA1, with supporting evidence, from the corpus.
A3Direct factual retrievalgeneticseasyAnswerableAccording to the corpus, what fraction of breast cancer cases are attributable to hereditary causes, and which gene is cited as the main cause of the familial forms?
B2Evidence aggregationdrug interactionsmediumAnswerableAccording to the corpus, what class of drug exploits homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers, and what is the general premise of this therapeutic approach?
E2Multi-hop synthesispathwayshardAnswerableChain together, using two separate documents in the corpus, how a BRCA2 germline pathogenic variant creates a specific drug-treatable vulnerability: what DNA repair process does BRCA2 support, and what class of drug exploits its loss?
A4Direct factual retrievalpathwayseasyAnswerableAccording to the corpus, which signaling pathway is frequently altered in gynecological tumors like PIK3CA-mutated endometrial cancer, and what investigational drug for this target is described being trialed?
C2Comparisonbioinformatics methodologymediumAnswerableCompare SynthDNM and elPrep 5 as described in the corpus: what stage of a variant-calling pipeline does each tool address?
B3Evidence aggregationbioinformatics methodologymediumAnswerableWhat evidence does the corpus provide about limitations of existing variant-filtering methods in NGS analysis pipelines, and how do the cited documents propose addressing them?
T1
cutoff <2021
temporal_cutoffprotein biologyhardAnswerableBased only on literature published before 2021 in the corpus, what ubiquitin ligase regulates the MDM2-p53 pathway, and how?
G3Insufficient evidence (trap)disease mechanismsmediumTrap — no answer existsDoes the corpus provide evidence that growth hormone (GH)-IGF axis signaling regulates TP53 mutation status in cancer?
G4Insufficient evidence (trap)protein biologymediumTrap — no answer existsDoes the corpus provide evidence that Integrin alpha-3 (ITGA3) directly regulates BRCA1-mediated DNA repair?
B4Evidence aggregationdisease mechanismsmediumAnswerableIn which hematologic malignancies does the corpus describe TP53 status as prognostically significant, and for which is a specific patient population or predictive role noted?
C3Comparisondrug interactionsmediumAnswerableCompare CDK4/6 inhibitors and PARP inhibitors as described in the corpus: what breast/gynecological cancer contexts and mechanisms does each target?

These tasks were constructed by a single researcher directly from real corpus text (“researcher-constructed,” not an expert panel — see methods). Every acceptable-answer concept is traceable to a specific abstract via each task’s construction note in the repo.